ROIVANT SCIENCES LTD (ROIV)
BMG762791017 - Common Stock
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference...
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.
Roivant Sciences Breaks Above 200-Day Moving Average - Bullish for ROIV
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira.
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase...
Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading.
Noteworthy Friday Option Activity: ROIV, CSGP, PII
Roivant Sciences (ROIV) Shares Cross Below 200 DMA
(NASDAQ:ROIV)
Roivant Sciences surpasses expectations in Q3 financial results with a GAAP EPS of $6.03, beating estimates by $5.54, and revenue of $37.14M, surpassing...
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third...
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
BASEL, Switzerland and LONDON and NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference...
Interesting ROIV Put Options For October 2025
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Roivant Sciences Larger Than S&P 500 Component Catalent
Vivek Ramaswamy sells $33M Roivant stock (NASDAQ:ROIV)
U.S. presidential candidate Vivek Ramaswamy sells over $33M worth of Roivant Sciences (ROIV) shares to finance his campaign. Read more here.
Ramaswamy Sells $33 Million Worth of Roivant Shares as Primaries Approach
Vivek Ramaswamy sold about $33 million worth of shares in his biotech company Roivant Sciences Ltd., continuing to largely fund his presidential campaign with his own money.
First Week of August 2024 Options Trading For Roivant Sciences (ROIV)
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for...
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously...